Quebec City, Canada; Endoceutics announces that the U.S. commercial rights for its flagship product, INTRAROSA®, were transferred to Millicent Pharma following a divestiture process announced in January 2020 by AMAG Pharmaceuticals.
Quebec City, Canada; Endoceutics is happy to announce the approval of INTRAROSA by Health Canada for the treatment of postmenopausal vulvovaginal atrophy.
Québec City, Canada; Endoceutics announced today that Dennis Turpin, President and Chief Executive Officer of Endoceutics, is scheduled to present an overview of the company at the Bloom Burton & Co. Healthcare Investor Conference.